MAXHEALT
Max Healthcare delivered slightly better-than-expected revenue and in-line EBITDA in 1QFY27, though adj. PAT missed expectations due to higher depreciation and interest costs. Considering superior operating efficiency at current hospitals and a robust capex path, we maintain our BUY rating.
Ratings and target prices as published by each firm. Each summary condenses that firm's stated view in its own note and is attributed to it; no report text is reproduced.
